Publications
2026
Tully MK, Commons RJ, Simpson JA, Price DJ: Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches. Br J Clin Pharmacol 2026, 92:317-322.
Moss R, Dini S, Kho S, Barber BE, Buffet PA, Rajasekhar M, Price DJ, Anstey NM, Simpson JA: The role of the spleen in red blood cell loss caused by malaria: A mathematical model. PLoS Comput Biol 2026, 22:e1013865.
2025
Peixoto HM, Bastos Gottin LL, de Brito-Sousa JD, Sampaio V, Daumerie PG, Jambert E, Monteiro WM, Lacerda MVG, Devine A. The cost-effectiveness of tafenoquine following screening with STANDARDTM G6PD screening for the treatment of vivax malaria in the Brazilian Public Health System. Lancet Regional Health - Americas 2025; 51:101216, 1-10.
Abraham P, Lubis IN, Noviyanti R, Trianty L, Nisa FA, Kariodimedjo P, Amalia R, Cahyadi RAD, Qorny TMA, Perlambang R, Surendra H, Anstey N, Grigg MJ, Devine A (joint senior author). The household economic burden of human-only and zoonotic malaria, compared to other causes of acute febrile illness in Indonesia. BMJ Global Health 11:e020504, 1-11.
Setiawan E, Devine A, Sugairsih, Prameswari HD, Baird JK, Price RN, Thriemer K. Malaria Morbidity, Mortality, and Hospitalization Costs in Indonesia: Analysis of National Health Insurance Claim Datasets. BMJ Global Health 2025; 10:e018255, 1-9.
Abraham P, McMullin C, William T, Rajahram GS, Jelip J, Teo R, Drakeley C, Manah AM, Anstey NM, Grigg MJ, Devine A (joint senior author). Household costs associated with zoonotic Plasmodium knowlesi, P. falciparum, P. vivax, and P. malariae episodes in Sabah, Malaysia. PLoS Negl Trop Dis 2025; 19(4):e0012180, 1-1
Edler P,… Commons RJ, Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis. Malar J. 2025 Nov 14;24(1):400. doi: 10.1186/s12936-025-05642-w.
2024
Price DJ, Nekkab N, Monteiro WM, Villela DAM, Simpson JA, Lacerda MVG, White M, Devine A. The cost-effectiveness of tafenoquine following G6PD screening for the treatment of vivax malaria in Brazil: a transmission model analysis. PLOS Medicine 2024; 21(1):e1004255, 1-17
Tully MK, Dini S, Flegg JA, McCarthy JS, Price DJ, Simpson JA: Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs. Antimicrob Agents Chemother 2024, 68:e0086324.
Cao P, Kho S, Grigg MJ, Barber BE, Piera KA, William T, Poespoprodjo JR, Jang IK, Simpson JA, McCaw JM, Anstey NM, McCarthy JS, Britton S: Characterisation of Plasmodium vivax lactate dehydrogenase dynamics in P. vivax infections. Commun Biol 2024, 7:355.
Harrison, L.E., Flegg, J.A., Tobin, R., Lubis, I.N.D., Noviyanti, R., Grigg, M.J., Shearer, F.M. & Price, D.J. (2024). A multi-criteria framework for disease surveillance site selection: case study for Plasmodium knowlesi malaria in Indonesia. Royal Society Open Science, 11(1), 230641.
Fadilah I, Commons RJ, et al, Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis. PLoS Med. 2024 Sep 27;21(9):e1004411. doi: 10.1371/journal.pmed.1004411.
Commons RJ, et al, Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. Lancet Child Adolesc Health. 2024 Nov;8(11):798-808. doi: 10.1016/S2352-4642(24)00210-4.
2023
Walker CR, Hickson RI, Chang E, Ngor P, Sovannaroth S, Simpson JA, Price DJ, McCaw JM, Price RN, Flegg J, Devine A. A model for malaria treatment evaluation in the presence of multiple species. Epidemics 2023; 44:100687, 1-9.
Haghiri A, Price DJ, Fitzpatrick P, Dini S, Rajasekhar M, Fanello C, Tarning J, Watson J, White NJ, Simpson JA: Evidence based optimal dosing of intravenous artesunate in children with severe falciparum malaria. Clin Pharmacol Ther 2023.
Saralamba S, Simpson JA, Choosri N, White L, Pan-Ngum W, Dondorp AM, White NJ: An artesunate pharmacometric model to explain therapeutic responses in falciparum malaria. J Antimicrob Chemother 2023.
Commons RJ, et al, Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis, Lancet Infectious Diseases. 2023 Sep 22:S1473-3099(23)00430-9. doi: 10.1016/S1473-3099(23)00430-9
Rajasekhar M,… Commons RJ, Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis, Lancet Infectious Diseases. 2023 Sep 22:S1473-3099(23)00431-0. doi: 10.1016/S1473-3099(23)00431-0
2022
Watson JA, Commons RJ (co-first author),…. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis, eLife 2022, 11: e83433. doi: 10.7554/eLife.83433
2021
Devine A, Battle KE, Meagher N, Howes RE, Dini S, Gething P, Simpson JA, Price RN, Lubell Y. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study. PLoS Medicine 2021; 18(6):e1003614, 1-20.
Zaloumis SG, Whyte JM, Tarning J, Krishna S, McCaw JM, Cao P, White MT, Dini S, Fowkes FJI, Maude RJ, Kremsner P, Dondorp A, Price RN, White NJ, Simpson JA: Development and Validation of an In Silico Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrob Agents Chemother 2021, 65.
Dini S, Zaloumis SG, Price DJ, Gobeau N, Kummel A, Cherkaoui M, Moehrle JJ, McCarthy JS, Simpson JA: Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. J Antimicrob Chemother 2021.
2020
Agius PA, Cutts JC, Win Han Oo, Aung Thi, O'Flaherty K, Kyaw Zayar Aung, Htin Kyaw Thu, Poe Poe Aung, Myat Mon Thein, Nyi Nyi Zaw, Wai Yan Min Htay, Aung Paing Soe, Razook Z, Barry AE, Win Htike, Devine A, Simpson JA, Crabb BS, Beeson JG, Pasricha N, Fowkes FJI. Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: a stepped-wedge cluster randomised trial. PLoS Medicine 2020; 17(8):e1003177, 1-21.
Devine A, Howes RE, Price DJ, Moore KA, Ley B, Simpson JA, Dittrich S, Price RN. Cost-effectiveness analysis of sex-stratified Plasmodium vivax treatment strategies using available G6PD diagnostics to accelerate access to radical cure. AJTMH 2020; 103(1):394-403. [ABCF, 80%]
Vlazaki, M., Price, D.J. & Restif, O. (2020). An experimental design tool to optimize inference precision in data-driven mathematical models of bacterial infections in vivo. Journal of the Royal Society Interface, 17(173), 20200717.
Lydeamore, M.J., Campbell, P.T., Price, D.J., Wu, Y., Marcato, A.J., Cuningham, W., Carapetis, J.R., Andrews, R.M., McDonald, M.I. & McVernon, J. (2020). Estimation of the force of infection and infectious period of skin sores in remote Australian communities using interval-censored data. PLOS Computational Biology, 16(10), e1007838.
2019
Devine A, Pasaribu AP, Teferi T, Pham HT, Awab GR, Contantia F, Nguyen TN, Ngo VT, Tran H, Hailu A, Gilchrist K, Green JA, Koh GCKW, Thriemer K, Taylor WR, Day NPJ, Price RN, Lubell Y. Provider and household costs of vivax malaria episodes: A multicountry comparative analysis of primary trial data. WHO Bulletin 2019; 97(12):828-836.
Cao P, Collins KA, Zaloumis S, Wattanakul T, Tarning J, Simpson JA, McCarthy J, McCaw JM: Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection. Elife 2019, 8:e49058.
Commons RJ, Simpson JA, Thriemer K, et al., The risk of Plasmodium vivax parasitaemia after P. falciparum infection: a systematic review and meta-analysis, Lancet Infectious Diseases, 2019; 19(1): 91-101. doi: 10.1016/S1473-3099(18)30596-6
Commons RJ, Simpson JA, Thriemer K, et al., The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis, BMC Medicine, 2019; 17(1): 151. doi: 10.1186/s12916-019-1386-6
Commons RJ, Simpson JA, Thriemer K, et al., The effect of dihydroartemisinin-piperaquine and artemether-lumefantrine on the risk of Plasmodium vivax: an individual patient pooled analysis, PLOS Medicine, 2019; 16(10): e1002928. doi: 10.1371/journal.pmed.1002928
2018
Zaloumis SG, Cao P, Dini S, Davenport MP, Cromer D, Khoury DS, Fowkes FJI, McCaw JM, SimpsonJA: In silico investigation of the decline in clinical efficacy of artemisinin combination therapies due to increasing artemisinin and partner drug resistance. Antimicrob Agents Chemother 2018, 62.
Dini S, Zaloumis S, Cao P, Price RN, Fowkes FJI, van der Pluijm RW, McCaw JM, Simpson JA: Investigating the efficacy of triple artemisinin-based combination therapies (TACTs) for treating Plasmodium falciparum malaria patients using mathematical modelling. Antimicrob Agents Chemother 2018, 62:e01068-01018.
Price, D.J., Bean, N.G., Ross, J.V. & Tuke, J. (2018a). An induced natural selection heuristic for finding optimal Bayesian experimental designs. Computational Statistics & Data Analysis, 126, 112–124.
Price, D.J., Bean, N.G., Ross, J.V. & Tuke, J. (2018b). Designing group dose-response studies in the presence of transmission. Mathematical Biosciences, 304, 62–78.
Commons RJ, Simpson JA, Thriemer K, et al., The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis, Lancet Infectious Diseases, 2018; 18: 1025-1034. doi: 10.1016/S1473-3099(18)30348-7
-2017
Jamsen, K.M., Duffull, S.B., Tarning, J. et al. (2011) Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J 10, 181.
Jamsen, K.M., Duffull, S.B., Tarning, J. et al. (2013) A robust design for identification of the Parasite Clearance Estimator. Malaria Journal, 12(410).
Price, D.J., Bean, N.G., Ross, J.V. & Tuke, J. (2016). On the efficient determination of optimal Bayesian experimental designs using ABC: A case study in optimal observation of epidemics. Journal of Statistical Planning and Inference, 172, 1–15.